CyRL-QN15

CyRL-QN15
Chemical and physical data
FormulaC40H52N10O10S3
Molar mass929.10 g·mol−1
3D model (JSmol)
  • O=C(O)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CSSC1)CCC(=O)N)Cc1ccccc1)Cc1[NH]cnc1)Cc1ccc(O)cc1)CCSC
  • InChI=InChI=1S/C40H52N10O10S3/c1-61-14-13-28-36(55)50-32(40(59)60)20-63-62-19-26(41)34(53)45-27(11-12-33(42)52)35(54)47-29(15-22-5-3-2-4-6-22)38(57)49-31(17-24-18-43-21-44-24)39(58)48-30(37(56)46-28)16-23-7-9-25(51)10-8-23/h2-10,18,21,26-32,51H,11-17,19-20,41H2,1H3,(H2,42,52)(H,43,44)(H,45,53)(H,46,56)(H,47,54)(H,48,58)(H,49,57)(H,50,55)(H,59,60)/t26-,27-,28-,29-,30-,31-,32-/m0/s1
  • Key:CDGOXQBMPZQUIZ-YYGRSCHNSA-N

CyRL-QN15 is a cyclic heptapeptide derivative with the sequence -CQFHYMC-, linked by a disulphide bond between the two cysteine residues. It was derived from peptides found in the skin secretions of the frog Rana limnocharis.[1][2] It enhances wound healing and has been researched for the treatment of diabetic ulcers. It has several different mechanisms of action, including acting as an antagonist at TLR4 and indirectly activating SIRT1.[3][4][5][6][7][8][9][10]

See also

References

  1. ^ Wang Y, Feng Z, Yang M, Zeng L, Qi B, Yin S, et al. (January 2021). "Discovery of a novel short peptide with efficacy in accelerating the healing of skin wounds". Pharmacological Research. 163 105296. doi:10.1016/j.phrs.2020.105296. PMID 33220421.
  2. ^ Wang X, Duan H, Li M, Xu W, Wei L (2023). "Characterization and mechanism of action of amphibian-derived wound-healing-promoting peptides". Frontiers in Cell and Developmental Biology. 11 1219427. doi:10.3389/fcell.2023.1219427. PMC 10309037. PMID 37397255.
  3. ^ Md Fadilah NI, Shahabudin NA, Mohd Razif RA, Sanyal A, Ghosh A, Baharin KI, et al. (2024). "Discovery of bioactive peptides as therapeutic agents for skin wound repair". Journal of Tissue Engineering. 15 20417314241280359. doi:10.1177/20417314241280359. PMC 11468004. PMID 39398382.
  4. ^ Wu YT, Ru ZQ, Peng Y, Fu Z, Jia QY, Kang ZJ, et al. (November 2024). "Peptide Cy RL-QN15 accelerates hair regeneration in diabetic mice by binding to the Frizzled-7 receptor". Zoological Research. 45 (6): 1287–1299. doi:10.24272/j.issn.2095-8137.2024.134. PMC 11668943. PMID 39479995.
  5. ^ Jia Q, Fu Z, Li Y, Kang Z, Wu Y, Ru Z, et al. (March 2024). "Hydrogel Loaded with Peptide-Containing Nanocomplexes: Symphonic Cooperation of Photothermal Antimicrobial Nanoparticles and Prohealing Peptides for the Treatment of Infected Wounds". ACS Applied Materials & Interfaces. 16 (11): 13422–13438. Bibcode:2024AAMI...1613422J. doi:10.1021/acsami.3c16061. PMID 38442213.
  6. ^ Wei Z, Li X, Zhou J, Zhou Y, Xiao Z, Yang Q, et al. (April 2025). "Inhibition of miRNA-365-2-5p Targeting SIRT1 Regulates Functions of Keratinocytes to Enhance Wound Healing". FASEB Journal. 39 (8) e70560. doi:10.1096/fj.202401124RRR. PMID 40261275.
  7. ^ Wang L, Fu Z, Su Y, Yin W, Wang X, Zhao W, et al. (September 2025). "Cyclic Heptapeptide FZ1 Acts as an Integrin αvβ3 Agonist to Facilitate Diabetic Skin Wound Healing by Enhancing Angiogenesis". Journal of Medicinal Chemistry. 68 (18): 19503–19520. doi:10.1021/acs.jmedchem.5c01734. PMID 40910702.
  8. ^ Kang Z, Yin S, Han X, Liu X, Peng Y, Jia Q, et al. (July 2025). "Peptide CyRL-QN15 alleviates UVB-induced skin aging by promoting the repair of barrier". Ecotoxicology and Environmental Safety. 300 118465. doi:10.1016/j.ecoenv.2025.118465. PMID 40472691.
  9. ^ Ru ZQ, Wu YT, Yang CY, Yang YT, Li YJ, Liu M, et al. (September 2025). "Ultra-short cyclic peptide Cy RL-QN15 acts as a TLR4 antagonist to expedite oral ulcer healing". Zoological Research. 46 (5): 1187–1202. doi:10.24272/j.issn.2095-8137.2025.211. PMC 12780494. PMID 41017403.
  10. ^ Ni D, Liu N, Peng Y, Li Y, Zhang S, Ru Z, et al. (September 2025). "MiR-181d-5p affects skin wound healing processes via the Ikbkg/NF-κB axis". International Journal of Biological Macromolecules. 322 (Pt 4) 147007. doi:10.1016/j.ijbiomac.2025.147007. PMID 40840735.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.